BMB-101 in Epilepsy With Eyelid Myoclonia (EEM) - Trial NCT06401538
Access comprehensive clinical trial information for NCT06401538 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bright Minds Biosciences Pty Ltd and is currently Not yet recruiting. The study focuses on Jeavons Syndrome. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bright Minds Biosciences Pty Ltd
Timeline & Enrollment
Phase 2
Jul 15, 2024
Oct 15, 2025
Primary Outcome
Change from baseline in seizure frequency
Summary
The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in
 reducing the frequency of seizures in subjects with Epilepsy with Eyelid Myoclonia (also
 called Jeavons Syndrome). The study will last up to 6 months. There will be a 1 month
 screening period, then 3 months on open-label BMB-101 including titration and
 tapering/washout periods, and then a 1 month follow-up period. There will be 7 clinic visits.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06401538
Non-Device Trial